Abatacept subcutaneous — Competitive Intelligence Brief

Abatacept subcutaneous (Abatacept subcutaneous) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: T-cell co-stimulation modulator. Area: Immunology.

phase 3 T-cell co-stimulation modulator CD80/CD86 Immunology Small molecule

Target snapshot

Abatacept subcutaneous (Abatacept subcutaneous) — Bristol-Myers Squibb. Abatacept is a fusion protein that blocks T-cell co-stimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and reducing inflammatory responses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Abatacept subcutaneous TARGET	Abatacept subcutaneous	Bristol-Myers Squibb	phase 3	T-cell co-stimulation modulator	CD80/CD86
abatacept infusion	abatacept infusion	University of Minnesota	marketed	T-cell costimulation inhibitor	CD80/CD86
IV Abatacept	IV Abatacept	Rüdiger B. Müller	marketed	T-cell costimulation inhibitor	CD80/CD86
abatacept (ABA)	abatacept (ABA)	Bristol-Myers Squibb	marketed	CTLA-4 immunoglobulin fusion protein	CD80/CD86
ABT	ABT	Shanghai Public Health Clinical Center	marketed	CTLA-4 modulator	CD80/CD86
Open-label Abatacept	Open-label Abatacept	Bristol-Myers Squibb	phase 3	CTLA-4 fusion protein (T-cell costimulation inhibitor)	CD80/CD86
PLA + MTX switched to ABA+ MTX, DB	PLA + MTX switched to ABA+ MTX, DB	Bristol-Myers Squibb	phase 3	T-cell costimulation inhibitor	CD80/CD86 (on antigen-presenting cells); CD28 (on T cells)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (T-cell co-stimulation modulator class)

1. Bristol-Myers Squibb · 1 drug in this class